Phaseline

Targets › ERBB4

ERBB4 (Receptor tyrosine-protein kinase erbB-4): drug programs, companies and trials

32 programs from 29 companies in 39 trials: 24 Phase 2, 11 Phase 1, 3 Phase 3, 1 Phase 4; Oncology; next expected readout Dec 2026.

Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. (UniProt, Q15303)

Open in Phaseline: the race on ERBB4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Michael HoppAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 4Non-squamous NSCLCDec 2026
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 3Early-stage Breast CancerFeb 2028
Region SkaneAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 3Non-Small Cell Lung CancerSep 2028
Region SkaneDacomitinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 3Non-Small Cell Lung CancerSep 2028
National University Hospital, SingaporeAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2NSCLCDec 2026
Yale UniversityAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2HER2/Neu+ Uterine Serous CarcinomaDec 2026
Ruth O'ReganNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Breast CancerDec 2026
National Cancer Institute (NCI)Afatinib Dimaleate
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Advanced LymphomaJan 2027
H. Lee Moffitt Cancer Center and Research InstituteAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Squamous Cell CarcinomaFeb 2027
National Cancer Institute (NCI)Neratinib Maleate
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Malignant Female Reproductive System Neoplasm; Metastatic Malignant Solid NeoplasmFeb 2027
National Cancer Centre, SingaporeDacomitinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2NSCLC Stage IIIB; Advanced Solid TumoursApr 2027
Shanghai Chest HospitalDacomitinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Non-small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer (NSCLC)May 2027
University Health Network, TorontoNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Breast CancerJul 2027
University of Texas Southwestern Medical CenterAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Advanced Squamous Non Small Cell Lung CancerSep 2027
University of RochesterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Breast CancerSep 2027
National Taiwan University HospitalAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2NSCLC Stage IVOct 2027
Massachusetts General HospitalAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Lung Cancer; Advanced Solid TumorDec 2027
Shandong Public Health Clinical CenterAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Carcinoma, Non-Small-Cell LungDec 2027
David Reardon, MDNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2GlioblastomaFeb 2028
H. Lee Moffitt Cancer Center and Research InstituteNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2GastroEsophageal CancerMar 2028
Fudan UniversityNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Breast Cancer With Brain MetastasisAug 2029
Scott R. Plotkin, MD, PhDNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Neurofibromatosis Type 2Dec 2029
Spanish Breast Cancer Research GroupNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Early-stage Breast CancerJan 2030
Vanderbilt-Ingram Cancer CenterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Anatomic Stage I Breast CancerApr 2030
Dartmouth-Hitchcock Medical CenterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 2Advanced Breast CancerOct 2030
Jeeyun LeeAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Stomach NeoplasmDec 2026
West China HospitalAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1HNSCC; Esophagus CancerMay 2027
Fox Chase Cancer CenterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Gastric CancerJun 2027
Memorial Sloan Kettering Cancer CenterNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Solid TumorOct 2027
Virginia Commonwealth UniversityNeratinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Advanced Solid TumorOct 2027
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Fanconi AnemiaDec 2028
China Medical University HospitalAfatinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor
EGFR, ERBB2, ERBB4Phase 1Non-small Cell Lung Cancer–

Conditions

Breast Cancer (3) Advanced Lymphoma (3) Advanced Solid Tumor (2) Non-Small Cell Lung Cancer (2) Early-stage Breast Cancer (2) Non-squamous NSCLC (1) Non-small Cell Lung Cancer (1) NSCLC Stage IV (1) Squamous Cell Carcinoma (1) Lung Cancer (1) Solid Tumor (1) GastroEsophageal Cancer (1)

Modalities

small molecule (23), mixed (7), antibody (1)

Companies

H. Lee Moffitt Cancer Center and Research Institute (2) Region Skane (2) National Cancer Institute (NCI) (2) Michael Hopp (1) China Medical University Hospital (1) National Taiwan University Hospital (1) Massachusetts General Hospital (1) University Health Network, Toronto (1) Memorial Sloan Kettering Cancer Center (1) Fox Chase Cancer Center (1) Shanghai Chest Hospital (1) Scott R. Plotkin, MD, PhD (1) Jeeyun Lee (1) National University Hospital, Singapore (1) Fudan University (1) Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) University of Rochester (1) Dartmouth-Hitchcock Medical Center (1) Spanish Breast Cancer Research Group (1) National Cancer Centre, Singapore (1)

Related targets

EGFR (32) ERBB2 (32)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.